Security
LXEO · Lexeo Therapeutics, Inc.
LXEONASDAQCommon stockCurrentCIK 1907108Updated Sep 26, 2026
LXEO price & chart
Loading TradingView…
NASDAQ:LXEO on TradingView ↗About the company
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
In the news
Recent filings
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
144 filing
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 268,688,000Source | 146,942,000Source | 139,807,000Source | 97,076,000Source |
| Property, Plant and Equipment, NetUSD | 1,139,000Source | 1,028,000Source | 1,056,000Source | 998,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 63,000,000Source | 35,014,000Source | 121,466,000Source | 77,335,000Source |
| Assets, CurrentUSD | 188,392,000Source | 126,121,000Source | 124,294,000Source | 80,048,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,625,000Source | 4,603,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 6,578,000Source | 8,069,000Source | 9,442,000Source | 10,708,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 22,019,000Source | 30,100,000Source | 26,272,000Source | 24,997,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 7,000Source | 3,000Source | 3,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -380,134,000Source | -280,173,000Source | -181,840,000Source | -115,446,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 188,000Source | -103,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 246,669,000Source | 116,842,000Source | 113,535,000Source | -112,954,000Source |
| Additional Paid in Capital, Common StockUSD | 626,625,000Source | 397,132,000Source | 295,372,000Source | 2,492,000Source |
| Liabilities and EquityUSD | 268,688,000Source | 146,942,000Source | 139,807,000Source | 97,076,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 16,808,000Source | 22,846,000Source | 17,239,000Source | 14,349,000Source |
| Operating Lease, Liability, CurrentUSD | 2,157,000Source | 2,100,000Source | 2,087,000Source | 2,287,000Source |
| Accounts Payable, CurrentUSD | 4,856,000Source | 6,417,000Source | 3,794,000Source | 2,678,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,884,000Source | 6,437,000Source | 7,786,000Source | 9,000,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 128,500,000Source | — | — |
| Short-term InvestmentsUSD | — | 86,504,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -99,961,000Source | -98,333,000Source | -66,394,000Source | -59,277,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 12,132,000Source | 12,474,000Source | 3,043,000Source | 1,781,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -1,561,000Source | 2,378,000Source | -180,000Source | -426,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -98,561,000Source | -81,151,000Source | -59,496,000Source | -54,560,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -90,252,000Source | -94,077,000Source | -165,000Source | -901,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 397,000Source | 481,000Source | 115,000Source | 672,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 216,795,000Source | 88,776,000Source | 103,791,000Source | 189,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 27,982,000Source | -86,452,000Source | 44,130,000Source | -55,272,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 66,248,000Source | 38,266,000Source | 124,718,000Source | 80,588,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 104,000Source | 127,000Source | 176,000Source | 77,000Source |
| Income Taxes Paid, NetUSD | 551,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 12,132,000Source | 12,474,000Source | 3,043,000Source | 1,781,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 128,500,000Source | — | — |
| General and Administrative ExpenseUSD | 45,460,000Source | 31,675,000Source | 15,383,000Source | 12,001,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | 95,000Source | 137,000Source | — | — |
| Investment Income, InterestUSD | 6,130,000Source | 7,556,000Source | 2,867,000Source | 1,325,000Source |
| Net Income (Loss) Attributable to ParentUSD | -99,961,000Source | -98,333,000Source | -66,394,000Source | -59,277,000Source |
| Nonoperating Income (Expense)USD | 9,296,000Source | 7,433,000Source | 2,119,000Source | 1,232,000Source |
| Operating ExpensesUSD | 109,257,000Source | 105,766,000Source | 68,513,000Source | 61,163,000Source |
| Operating Lease, ExpenseUSD | 2,650,000Source | 2,606,000Source | 2,502,000Source | 1,795,000Source |
| Other Nonoperating Income (Expense)USD | -18,000Source | -9,000Source | -13,000Source | -2,000Source |
| Payments to Acquire InvestmentsUSD | 195,382,000Source | 93,596,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | 270,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 59,000Source | 491,000Source | 51,000Source | 332,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | 291,000Source | -103,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 654,000Source |
| Operating Income (Loss)USD | -109,257,000Source | -105,766,000Source | -68,513,000Source | -60,509,000Source |
| Other Nonoperating Income (Expense)USD | -18,000Source | -9,000Source | -13,000Source | -2,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -99,670,000Source | -98,333,000Source | -66,394,000Source | -59,277,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -99,961,000Source | -98,333,000Source | -66,394,000Source | -59,277,000Source |
| Earnings Per Share, BasicUSD per share | -1.86Source | -3.09Source | -12.4Source | -36.36Source |
| Earnings Per Share, DilutedUSD per share | -1.86Source | -3.09Source | -12.4Source | -36.36Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 53,645,323Source | 31,787,491Source | 5,354,368Source | 1,630,348Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 53,645,323Source | 31,787,491Source | 5,354,368Source | 1,630,348Source |
| Interest Expense (non-operating)USD | 95,000Source | 137,000Source | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 268,000Source | 304,000Source | 271,000Source | 120,000Source |
| General and Administrative ExpenseUSD | 45,460,000Source | 31,675,000Source | 15,383,000Source | 12,001,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -99,670,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 205,000Source | 91,000Source |
| Investment Income, InterestUSD | 6,130,000Source | 7,556,000Source | 2,867,000Source | 1,325,000Source |
| Nonoperating Income (Expense)USD | 9,296,000Source | 7,433,000Source | 2,119,000Source | 1,232,000Source |
| Operating ExpensesUSD | 109,257,000Source | 105,766,000Source | 68,513,000Source | 61,163,000Source |
| Operating Lease, ExpenseUSD | 2,650,000Source | 2,606,000Source | 2,502,000Source | 1,795,000Source |
| Research and Development ExpenseUSD | 63,797,000Source | 74,091,000Source | 53,130,000Source | 49,162,000Source |
Filing attachments
lxeo-ex99_1.htm · 8-K · 2026-09-22
Exhibit 99.1 Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease SUNR…
Read attachment ↗lxeo-ex99_2.htm · 8-K · 2026-09-22
Business Update September 22, 2026 Exhibit 99.2 1 This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, the timing for receipt and announcement of data from its clinical trials, the timing and likelihood of potential regulatory developments, trial design changes and ap…
Read attachment ↗lxeo-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 lxeo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identificati…
Read attachment ↗lxeo-ex99_2.htm · 8-K · 2026-08-12
EX-99.2 3 lxeo-ex99_2.htm EX-99.2 Lexeo Therapeutics Corporate Overview August 2026 Exhibit 99.2 Forward-looking statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, the timing for receipt and announcement of data from its clinical trials, the timing an…
Read attachment ↗lxeo-ex99_1.htm · 8-K · 2026-06-15
EX-99.1 2 lxeo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design BLA supportive manufacturing strategy includes flexible process validation, including reduced PPQ manufacturing batches SUNRISE-FA 2 in…
Read attachment ↗lxeo-ex99_2.htm · 8-K · 2026-06-15
EX-99.2 3 lxeo-ex99_2.htm EX-99.2 Lexeo Therapeutics LX2006 Regulatory Update June 15, 2026 Exhibit 99.2 Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Lexeo’s expectations and plans regarding its current product candidates and programs, including statements regarding the structure of and timelines for completion of any current or additional clinical t…
Read attachment ↗